Evaluation of nafamostat mesilate as an alternative anticoagulant during intermittent hemodialysis in healthy Beagle dogs

Evaluation of nafamostat mesilate as an alternative anticoagulant during intermittent... AbbreviationsACTactivated clotting timeaPTTactivated partial thromboplastin timeCRRTcontinuous renal replacement therapyECCextracorporeal circulationHITheparin‐induced thrombocytopeniaIHDintermittent hemodialysisLMWHlow molecular weight heparinNMnafamostat mesilatePSpolysulfonePTprothrombin timeQbblood flow rateQddialysate flow rateQfultrafiltration rateUFHunfractionated heparinIntroductionAnticoagulation is required to prevent thrombosis when using extracorporeal circulation (ECC). Unfractionated heparin (UFH) is widely used as an anticoagulant agent for ECC in intermittent hemodialysis (IHD) in veterinary practice. In people, however, UFH is associated with adverse effects, including heparin‐induced thrombocytopenia (HIT) and increased incidence of hemorrhage (10–26%). Hemodialysis using UFH has been found to be associated with bleeding complications in 17.8% of dogs and 5.5% of all animals in a retrospective study.Systemic anticoagulation during hemodialysis increases the risk of blood loss, especially in patients with active hemorrhage, as well as in those who have experienced recent trauma or undergone surgery. There are several alternative anticoagulation methods to prevent clotting in the ECC, such as regional citrate anticoagulation, heparin/protamine regional anticoagulation, low molecular weight heparin (LMWH), and heparin‐free hemodialysis. However, these strategies also have limitations, including the potential for adverse events in patients at high risk of bleeding.Nafamostat mesilate (NM), a serine protease inhibitor originally developed to treat pancreatitis, has been used as an alternative anticoagulant in patients in Japan and South Korea at increased risk http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Veterinary Emergency and Critical Care Wiley

Evaluation of nafamostat mesilate as an alternative anticoagulant during intermittent hemodialysis in healthy Beagle dogs

Loading next page...
 
/lp/wiley/evaluation-of-nafamostat-mesilate-as-an-alternative-anticoagulant-UTHqP5otgC
Publisher
Wiley
Copyright
Copyright © 2018 Veterinary Emergency and Critical Care Society
ISSN
1479-3261
eISSN
1476-4431
D.O.I.
10.1111/vec.12696
Publisher site
See Article on Publisher Site

Abstract

AbbreviationsACTactivated clotting timeaPTTactivated partial thromboplastin timeCRRTcontinuous renal replacement therapyECCextracorporeal circulationHITheparin‐induced thrombocytopeniaIHDintermittent hemodialysisLMWHlow molecular weight heparinNMnafamostat mesilatePSpolysulfonePTprothrombin timeQbblood flow rateQddialysate flow rateQfultrafiltration rateUFHunfractionated heparinIntroductionAnticoagulation is required to prevent thrombosis when using extracorporeal circulation (ECC). Unfractionated heparin (UFH) is widely used as an anticoagulant agent for ECC in intermittent hemodialysis (IHD) in veterinary practice. In people, however, UFH is associated with adverse effects, including heparin‐induced thrombocytopenia (HIT) and increased incidence of hemorrhage (10–26%). Hemodialysis using UFH has been found to be associated with bleeding complications in 17.8% of dogs and 5.5% of all animals in a retrospective study.Systemic anticoagulation during hemodialysis increases the risk of blood loss, especially in patients with active hemorrhage, as well as in those who have experienced recent trauma or undergone surgery. There are several alternative anticoagulation methods to prevent clotting in the ECC, such as regional citrate anticoagulation, heparin/protamine regional anticoagulation, low molecular weight heparin (LMWH), and heparin‐free hemodialysis. However, these strategies also have limitations, including the potential for adverse events in patients at high risk of bleeding.Nafamostat mesilate (NM), a serine protease inhibitor originally developed to treat pancreatitis, has been used as an alternative anticoagulant in patients in Japan and South Korea at increased risk

Journal

Journal of Veterinary Emergency and Critical CareWiley

Published: Jan 1, 2018

Keywords: ; ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off